Overview
NextCure Q3 net loss decreases compared to same period last year
Company advances ADC programs with U.S. enrollment and FDA clearance for protocol amendment
Financial resources expected to fund operations into mid-2026
Outlook
NextCure's current financial resources expected to last into mid-2026
Result Drivers
ADC PROGRAM ADVANCEMENT - NextCure progressed ADC programs with U.S. enrollment for SIM0505 and FDA clearance for LNCB74 protocol amendment
Research and development expenses were $6.1 million for the three months ended September 30, 2025, as compared to $8.8 million for the three months ended September 30, 2024.
FINANCIAL RESOURCE MANAGEMENT - Cash reserves decreased due to operational funding and license fees, but expected to fund operations into mid-2026
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | -$8.62 mln | ||
Q3 Basic EPS | -$3.22 | ||
Q3 Income from Operations | -$8.95 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for NextCure Inc is $17.50, about 44.9% above its November 4 closing price of $9.64
Press Release: ID:nGNX4Ps7Pr
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)